| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-06-16 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week follow-up of abnormal bleeding and pelvic pain, with the biopsy, MRI and PET-CT results and gynecologic oncology consultation today. [S]
Mrs. Lovelace returns two weeks after her first visit, on the day of her consultation with Dr. Lindgren-Osei. She stopped the opium tincture as agreed and takes oral morphine solution 5 mg with the oral syringe, about six doses a day; her average pelvic pain over the past week is 6 of 10, and she is not drowsy. The bleeding continues, lighter than before, with a watery discharge. She is a little less breathless on stairs since the iron infusion. Her bowels open every other day on senna and polyethylene glycol. She had the MRI a week ago and the PET-CT five days ago. She asked to hear all the results herself and plainly. [S]
| Element | Detail |
|---|---|
| Pain | Average 6 of 10; oral morphine 5 mg about six times a day; not drowsy |
| Bleeding | Continuing, lighter; watery discharge |
| Anemia | Less breathless since the iron infusion |
| Bowels | Every other day on laxatives |
| Preference | Wants the results told to her directly |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever; weight steady |
| Genitourinary | Positive | Lighter bleeding and watery discharge; no urinary symptoms |
| Respiratory | Negative | No cough or hemoptysis |
| Gastrointestinal | Negative | Bowels every other day; no nausea |
| Psychiatric | Positive | Anxious about the results; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-16 | Body height | 165 | cm | S |
| 2026-06-16 | Body weight | 54.2 | kg | S |
| 2026-06-16 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 2026-06-16 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-06-16 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-06-16 | Heart rate | 92 | /min | S |
| 2026-06-16 | Respiratory rate | 16 | /min | S |
| 2026-06-16 | Body temperature | 36.7 | Cel | S |
| 2026-06-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-16 | Hemoglobin [Mass/volume] in Blood | 9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-06-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 | U/L | 7-35 U/L | Normal | S |
| 2026-06-16 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-06-16 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-06-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 117 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-06-16 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Vital signs recorded on 2026-06-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Pale and alert; blood pressure 106/66, pulse 92, weight 54.2 kg |
| Lymph nodes | No supraclavicular or inguinal lymph node enlargement |
| Respiratory | Clear to auscultation |
| Abdomen | Soft; mild suprapubic tenderness; no masses or liver enlargement |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 9.0 g/dL; full count before the first cycle |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.66 mg/dL, eGFR 117, ALT 17 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | Baseline TSH 1.9 mIU/L, free T4 1.2 ng/dL before pembrolizumab |
| Laboratory | HIV, hepatitis B and hepatitis C before cancer treatment | Once, before treatment | Completed today | All negative; hepatitis B surface antibody negative, so vaccination is due |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Due | Due 6 to 8 weeks after today's second infusion |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | Continuing, lighter; no transfusion needed |
| Imaging | Staging: pelvic MRI and PET-CT | At diagnosis | Completed today | Stage IVB by imaging; lung biopsy to confirm |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 6 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation, confusion or nausea |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Every other day on senna and polyethylene glycol |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change | Completed today | Naloxone at home; locked storage; one prescriber; monitoring check clear |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | At diagnosis and periodically | Up to date | PHQ-9 8 at the first visit; anxious today |
| Referral | Specialist palliative care | From diagnosis of advanced cancer | Completed today | First palliative care visit today |
| Referral | Gynecologic oncology consultation | Once, at diagnosis | Completed today | Seen by Dr. Lindgren-Osei today |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)
Follow-up: Lung biopsy and pelvic radiation in the next ten days. Six-week review in four weeks. Next scheduled visit 2026-07-14: six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety. [S]